Physician profile
Tara Atta
NPI 1639166374
$4,415.93
in general payments reported to CMS, 2019-2025
17 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $157 · 2021: $725 · 2022: $585 · 2023: $756 · 2024: $1,076 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,469.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $625.51 | 2019-2025 | Xarelto, Opsynvi, Uptravi |
| Novo Nordisk INC | $530.39 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.99 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $333.66 | 2019-2025 | Camzyos |
| Amgen INC. | $244.00 | 2022-2025 | Repatha, Repatha |
| Medtronic, INC. | $178.67 | 2023-2025 | Linq II, Selectsecure, Corevalve Evolut R |
| Edwards Lifesciences Corporation | $161.65 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $119.23 | 2021-2024 | Farxiga, Brilinta |
| Amarin Pharma, INC. | $111.81 | 2019 | |
| Abbott Laboratories | $102.56 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $55.84 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $32.82 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $25.97 | 2025 | Attruby |
| Lilly USA, LLC | $23.07 | 2024 | Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $15.73 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $13.88 | 2025 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Atta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.